S. Peter Eggleton

1.0k total citations
21 papers, 618 citations indexed

About

S. Peter Eggleton is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, S. Peter Eggleton has authored 21 papers receiving a total of 618 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in S. Peter Eggleton's work include Lung Cancer Treatments and Mutations (11 papers), Cancer Treatment and Pharmacology (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). S. Peter Eggleton is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Cancer Treatment and Pharmacology (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). S. Peter Eggleton collaborates with scholars based in Germany, France and United States. S. Peter Eggleton's co-authors include Simon Payne, Tarun K. Sarkar, Leslie G. Walker, Andrew W. Hutcheon, Keith N. Ogston, Fiona J. Gilbert, Oleg Eremin, Ian C. P. Smith, Iain D. Miller and Steven D. Heys and has published in prestigious journals such as Journal of Clinical Oncology, Hepatology and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

S. Peter Eggleton

20 papers receiving 601 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Peter Eggleton Germany 9 418 310 132 116 82 21 618
B Leone Argentina 14 446 1.1× 200 0.6× 170 1.3× 133 1.1× 120 1.5× 36 693
Massimo Rinaldo Italy 15 307 0.7× 299 1.0× 147 1.1× 104 0.9× 81 1.0× 29 690
Rita Abi‐Raad United States 12 240 0.6× 232 0.7× 135 1.0× 139 1.2× 142 1.7× 33 608
Pieter‐Jan van Dam Belgium 16 335 0.8× 278 0.9× 41 0.3× 209 1.8× 68 0.8× 37 684
László Mangel Hungary 11 226 0.5× 202 0.7× 105 0.8× 136 1.2× 70 0.9× 63 511
IE Smith United Kingdom 6 257 0.6× 230 0.7× 88 0.7× 121 1.0× 50 0.6× 9 577
Klaus Kluck Germany 7 463 1.1× 255 0.8× 85 0.6× 249 2.1× 73 0.9× 16 715
JK Litton United States 5 536 1.3× 238 0.8× 63 0.5× 295 2.5× 85 1.0× 19 733
Cristina Ferraris Italy 14 310 0.7× 432 1.4× 308 2.3× 91 0.8× 250 3.0× 44 890
Eisei Shin Japan 12 250 0.6× 163 0.5× 79 0.6× 121 1.0× 74 0.9× 30 485

Countries citing papers authored by S. Peter Eggleton

Since Specialization
Citations

This map shows the geographic impact of S. Peter Eggleton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Peter Eggleton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Peter Eggleton more than expected).

Fields of papers citing papers by S. Peter Eggleton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Peter Eggleton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Peter Eggleton. The network helps show where S. Peter Eggleton may publish in the future.

Co-authorship network of co-authors of S. Peter Eggleton

This figure shows the co-authorship network connecting the top 25 collaborators of S. Peter Eggleton. A scholar is included among the top collaborators of S. Peter Eggleton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Peter Eggleton. S. Peter Eggleton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Thomas, Michael, Petros Christopoulos, Wade T. Iams, et al.. (2025). MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy. Journal of Comparative Effectiveness Research. 14(2). e240127–e240127. 1 indexed citations
2.
Lim, Ho Yeong, Jeong Heo, Baek‐Yeol Ryoo, et al.. (2024). Efficacy and safety of bintrafusp alfa in 2 phase I expansion cohorts with advanced HCC. Hepatology. 81(1). 32–43. 4 indexed citations
3.
4.
Vokes, Everett E., F. Mornex, Ahmet Sezer, et al.. (2023). Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study. Journal of Thoracic Oncology. 19(2). 285–296. 13 indexed citations
5.
Morise, Masahiro, Hiroshi Sakai, Terufumi Kato, et al.. (2022). O13-4 Efficacy and intracranial activity of tepotinib in Japanese patients with MET exon 14 skipping (METex14) NSCLC (VISION). Annals of Oncology. 33. S475–S475. 1 indexed citations
6.
Manitz, Juliane, Sandra P. D’Angelo, Andrea B. Apolo, et al.. (2022). Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival. Journal for ImmunoTherapy of Cancer. 10(2). e003302–e003302. 24 indexed citations
7.
Patel, Jyoti D., Xiuning Le, Rémi Veillon, et al.. (2021). Intracranial activity of tepotinib in patients (pts) with MET exon 14 (METex14) skipping NSCLC enrolled in VISION.. Journal of Clinical Oncology. 39(15_suppl). 9084–9084. 8 indexed citations
8.
9.
10.
Douillard, Jean‐Yves, George Fountzilas, Carlo Barone, et al.. (2013). FOLFOX4 With Cetuximab vs. UFOX With Cetuximab as First-Line Therapy in Metastatic Colorectal Cancer: The Randomized Phase II FUTURE Study. Clinical Colorectal Cancer. 13(1). 14–26.e1. 21 indexed citations
11.
Douillard, Jean-Yves, George Fountzilas, Carlo Barone, et al.. (2012). O-0017 Randomized Phase II Study Evaluating Ufox Plus Cetuximab Versus Folfox4 Plus Cetuximab as First-Line Therapy in Metastatic Colorectal Cancer: Future. Annals of Oncology. 23. iv11–iv12. 4 indexed citations
12.
Wilke, H., Rob Glynne‐Jones, J. Thaler, et al.. (2006). MABEL—A large multinational study of cetuximab plus irinotecan in irinotecan resistant metastatic colorectal cancer. Journal of Clinical Oncology. 24(18_suppl). 3549–3549. 31 indexed citations
13.
Adenis, Antoine, Enrique Aranda, Y Robin, et al.. (2005). Expression of the epidermal growth factor receptor (EGFR or HER1) and human epidermal growth factor receptor 2 (HER2) in a large scale metastatic colorectal cancer (mCRC) trial. Journal of Clinical Oncology. 23(16_suppl). 3630–3630. 12 indexed citations
14.
Smith, Ian C. P., Steven D. Heys, Andrew W. Hutcheon, et al.. (2002). Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With Docetaxel. Journal of Clinical Oncology. 20(6). 1456–1466. 357 indexed citations
15.
Coleman, Robert E., et al.. (2000). A Phase II study of docetaxel in patients with liver metastases from breast cancer. Annals of Oncology. 11(5). 541–546. 12 indexed citations
16.
Vasey, P., James Paul, Elizabeth Junor, et al.. (1999). Docetaxel and Cisplatin in Combination as First-Line Chemotherapy for Advanced Epithelial Ovarian Cancer. Journal of Clinical Oncology. 17(7). 2069–2069. 66 indexed citations
17.
Hutcheon, Andrew W., S Heys, Ian Miller, et al.. (1999). Primary chemotherapy in breast cancer: Significantly enhanced clinical and pathological response with docetaxel. European Journal of Cancer. 35. S230–S230. 5 indexed citations
18.
O’Brien, Michelle, Robert Leonard, Peter Barrett‐Lee, S. Peter Eggleton, & J. P. Bizzari. (1999). Docetaxel in the community setting: An analysis of 377 breast cancer patients treated with docetaxel (Taxotere®) in the UK. Annals of Oncology. 10(2). 205–210. 37 indexed citations
19.
Eggleton, S. Peter, et al.. (1986). Heterotopic ossification of an expanded polytetrafluoroethylene vascular graft. British journal of surgery. 73(2). 159–160. 7 indexed citations
20.
Shelton, J. N., S. Peter Eggleton, & Jeffrey Wilkins. (1972). Effect of injection vehicle of progesterone on peripheral plasma progesterone levels and its relationship to fertility at controlled oestrus. Reproduction. 28(1). 152–153. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by B Leone Breakdown of academic impact, for papers by Massimo Rinaldo Breakdown of academic impact, for papers by Rita Abi‐Raad Breakdown of academic impact, for papers by Pieter‐Jan van Dam Breakdown of academic impact, for papers by László Mangel Breakdown of academic impact, for papers by IE Smith Breakdown of academic impact, for papers by Klaus Kluck Breakdown of academic impact, for papers by JK Litton Breakdown of academic impact, for papers by Cristina Ferraris Breakdown of academic impact, for papers by Eisei Shin
Rankless by CCL
2026